Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors

被引：0
|
作者：
Sabina Sandigursky
Adam Mor
机构：
[1] NYU School of Medicine,Department of Medicine
[2] NYU School of Medicine,Perlmutter Cancer Center
[3] Columbia University Medical Center,Columbia Center for Translational Immunology, Department of Medicine
来源：
Current Rheumatology Reports | 2018年 / 20卷
关键词：
Cancer; Checkpoint inhibitors; Adverse events; Autoimmune; irAEs;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
    Cook, Sarah
    Samuel, Vanessa
    Meyers, Daniel E.
    Stukalin, Igor
    Litt, Ishjot
    Sangha, Randeep
    Morris, Don G.
    Heng, Daniel Y. C.
    Pabani, Aliyah
    Dean, Michelle
    Navani, Vishal
    JAMA NETWORK OPEN, 2024, 7 (01) : E2352302
  • [42] Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors
    Pan, Catherina X.
    Liu, Mofei
    Lau, Charles B.
    Lau, William C.
    Kim, Daniel Y.
    Saberi, Shahin A.
    Rowley, Rachael
    Kanwar, Ruhi
    Giobbie-Hurder, Anita
    Leboeuf, Nicole R.
    Nambudiri, Vinod E.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (04) : 826 - 829
  • [43] Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors
    Serino, M.
    Freitas, C.
    Martins, M.
    Ferreira, P.
    Cardoso, C.
    Veiga, F.
    Santos, V.
    Araujo, D.
    Novais-Bastos, H.
    Magalhaes, A.
    Queiroga, H.
    Fernandes, G.
    Hespanhol, V.
    PULMONOLOGY, 2024, 30 (04): : 352 - 361
  • [44] Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: What Emergency Physicians Need to Know
    Peyrony, O.
    Mathe, S.
    Addou, S.
    Naud, N.
    Madelaine, I.
    Baroudjian, B.
    Lebbe, C.
    Fontaine, J. -P.
    ANNALES FRANCAISES DE MEDECINE D URGENCE, 2023, 13 (04): : 241 - 253
  • [45] Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors
    Titmuss, Emma
    Yu, Irene S.
    Pleasance, Erin D.
    Williamson, Laura M.
    Mungall, Karen
    Mungall, Andrew J.
    Renouf, Daniel J.
    Moore, Richard
    Jones, Steven J. M.
    Marra, Marco A.
    Laskin, Janessa J.
    Savage, Kerry J.
    CURRENT ONCOLOGY, 2024, 31 (04) : 1865 - 1875
  • [46] COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
    Chen, Yu-Wei
    Tucker, Matthew D.
    Beckermann, Kathryn E.
    Iams, Wade T.
    Rini, Brian I.
    Johnson, Douglas B.
    EUROPEAN JOURNAL OF CANCER, 2021, 155 : 291 - 293
  • [47] Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors
    Immanuel Augustin Oppolzer
    Josef Riester
    Roland Büttner
    Maximilian Burger
    Marco Julius Schnabel
    International Urology and Nephrology, 2023, 55 : 1943 - 1949
  • [48] Assessing the Relationship between Thrombosis and Immune-Related Adverse Events in Patients with Lung Cancer Treated with Immune Checkpoint Inhibitors
    Isaza, Daniela Arango
    O'Loughlin, Lauren
    Patell, Rushad
    Viray, Hollis
    Neuberg, Donna S.
    Dodge, Laura E.
    Rangachari, Deepa
    Asnani, Aarti
    Zwicker, Jeffrey, I
    Costa, Daniel
    BLOOD, 2022, 140 : 11372 - 11373
  • [49] Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors
    Oppolzer, Immanuel Augustin
    Riester, Josef
    Buettner, Roland
    Burger, Maximilian
    Schnabel, Marco Julius
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2023, 55 (08) : 1943 - 1949
  • [50] Management of Immune-Related Adverse Events Affecting Outcome in Patients Treated With Checkpoint Inhibitors
    Suijkerbuijk, Karijn P. M.
    Kapiteijn, Ellen
    Verheijden, Rik J.
    JAMA ONCOLOGY, 2020, 6 (08) : 1300 - +
12345